94 related articles for article (PubMed ID: 16520033)
1. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
2. Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.
Fiegl M; Mlineritsch B; Hubalek M; Bartsch R; Pluschnig U; Steger GG
BMC Cancer; 2011 Aug; 11():373. PubMed ID: 21864402
[TBL] [Abstract][Full Text] [Related]
3. Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial.
Orlando L; Maiello E; Orditura M; Diana A; Antoniol G; Morritti MG; Aieta M; Ciccarese M; Pisconti S; Bordonaro R; Russo A; Febbraro A; Schiavone P; Quaranta A; Caliolo C; Loparco D; Cinefra M; Colucci G; Cinieri S;
Breast; 2024 Jun; 75():103725. PubMed ID: 38615483
[TBL] [Abstract][Full Text] [Related]
4. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Colombo I; Koster KL; Holer L; Haefliger S; Rabaglio M; Bastian S; Schwitter M; Eckhardt K; Hayoz S; Mc Laughlin AM; Kloft C; Klose M; Halbherr S; Baumgartner C; Sessa C; Stathis A; Hess D; Joerger M
Eur J Cancer; 2024 Apr; 201():113588. PubMed ID: 38377773
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer.
Xu G; Yang D; He C; Zhong L; Zhu J; Shu Q; Ding H; Xin W; Tong Y; Zhu X; Fang L
Cancer Chemother Pharmacol; 2023 Sep; 92(3):181-192. PubMed ID: 37378676
[TBL] [Abstract][Full Text] [Related]
6. Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study.
Leonardi V; Palmisano V; Pepe A; Usset A; Manuguerra G; Savio G; DE Bella MT; Laudani A; Alù M; Cusimano MP; Scianna C; Giresi A; Agostara B
Oncol Lett; 2010 Jul; 1(4):749-753. PubMed ID: 22966374
[TBL] [Abstract][Full Text] [Related]
7. Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas.
Buonadonna A; Scalone S; Lombardi D; Fumagalli A; Guglielmi A; Lestuzzi C; Polesel J; Canzonieri V; Lamon S; Giovanis P; Gagno S; Corona G; Mascarin M; Belluco C; De Paoli A; Fasola G; Puglisi F; Miolo G
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894403
[TBL] [Abstract][Full Text] [Related]
8. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment.
Farr KP; Safwat A
Case Rep Oncol; 2011 Apr; 4(1):229-35. PubMed ID: 21537373
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Toxicity in a Laboratory Beagle (
Guerriero KA; Wilson SR; Boutagy NE; Liu C; Sinusas AJ; Zeiss CJ
Comp Med; 2018 Feb; 68(1):56-62. PubMed ID: 29460722
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers.
Radford J
J Clin Oncol; 2024 Jun; 42(16):1868-1870. PubMed ID: 38478798
[No Abstract] [Full Text] [Related]
11. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
13. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
Bojesen SE; Pooley KA; Johnatty SE; Beesley J; Michailidou K; Tyrer JP; Edwards SL; Pickett HA; Shen HC; Smart CE; Hillman KM; Mai PL; Lawrenson K; Stutz MD; Lu Y; Karevan R; Woods N; Johnston RL; French JD; Chen X; Weischer M; Nielsen SF; Maranian MJ; Ghoussaini M; Ahmed S; Baynes C; Bolla MK; Wang Q; Dennis J; McGuffog L; Barrowdale D; Lee A; Healey S; Lush M; Tessier DC; Vincent D; Bacot F; ; ; ; ; ; ; ; ; Vergote I; Lambrechts S; Despierre E; Risch HA; González-Neira A; Rossing MA; Pita G; Doherty JA; Alvarez N; Larson MC; Fridley BL; Schoof N; Chang-Claude J; Cicek MS; Peto J; Kalli KR; Broeks A; Armasu SM; Schmidt MK; Braaf LM; Winterhoff B; Nevanlinna H; Konecny GE; Lambrechts D; Rogmann L; Guénel P; Teoman A; Milne RL; Garcia JJ; Cox A; Shridhar V; Burwinkel B; Marme F; Hein R; Sawyer EJ; Haiman CA; Wang-Gohrke S; Andrulis IL; Moysich KB; Hopper JL; Odunsi K; Lindblom A; Giles GG; Brenner H; Simard J; Lurie G; Fasching PA; Carney ME; Radice P; Wilkens LR; Swerdlow A; Goodman MT; Brauch H; Garcia-Closas M; Hillemanns P; Winqvist R; Dürst M; Devilee P; Runnebaum I; Jakubowska A; Lubinski J; Mannermaa A; Butzow R; Bogdanova NV; Dörk T; Pelttari LM; Zheng W; Leminen A; Anton-Culver H; Bunker CH; Kristensen V; Ness RB; Muir K; Edwards R; Meindl A; Heitz F; Matsuo K; du Bois A; Wu AH; Harter P; Teo SH; Schwaab I; Shu XO; Blot W; Hosono S; Kang D; Nakanishi T; Hartman M; Yatabe Y; Hamann U; Karlan BY; Sangrajrang S; Kjaer SK; Gaborieau V; Jensen A; Eccles D; Høgdall E; Shen CY; Brown J; Woo YL; Shah M; Azmi MA; Luben R; Omar SZ; Czene K; Vierkant RA; Nordestgaard BG; Flyger H; Vachon C; Olson JE; Wang X; Levine DA; Rudolph A; Weber RP; Flesch-Janys D; Iversen E; Nickels S; Schildkraut JM; Silva Idos S; Cramer DW; Gibson L; Terry KL; Fletcher O; Vitonis AF; van der Schoot CE; Poole EM; Hogervorst FB; Tworoger SS; Liu J; Bandera EV; Li J; Olson SH; Humphreys K; Orlow I; Blomqvist C; Rodriguez-Rodriguez L; Aittomäki K; Salvesen HB; Muranen TA; Wik E; Brouwers B; Krakstad C; Wauters E; Halle MK; Wildiers H; Kiemeney LA; Mulot C; Aben KK; Laurent-Puig P; Altena AM; Truong T; Massuger LF; Benitez J; Pejovic T; Perez JI; Hoatlin M; Zamora MP; Cook LS; Balasubramanian SP; Kelemen LE; Schneeweiss A; Le ND; Sohn C; Brooks-Wilson A; Tomlinson I; Kerin MJ; Miller N; Cybulski C; Henderson BE; Menkiszak J; Schumacher F; Wentzensen N; Le Marchand L; Yang HP; Mulligan AM; Glendon G; Engelholm SA; Knight JA; Høgdall CK; Apicella C; Gore M; Tsimiklis H; Song H; Southey MC; Jager A; den Ouweland AM; Brown R; Martens JW; Flanagan JM; Kriege M; Paul J; Margolin S; Siddiqui N; Severi G; Whittemore AS; Baglietto L; McGuire V; Stegmaier C; Sieh W; Müller H; Arndt V; Labrèche F; Gao YT; Goldberg MS; Yang G; Dumont M; McLaughlin JR; Hartmann A; Ekici AB; Beckmann MW; Phelan CM; Lux MP; Permuth-Wey J; Peissel B; Sellers TA; Ficarazzi F; Barile M; Ziogas A; Ashworth A; Gentry-Maharaj A; Jones M; Ramus SJ; Orr N; Menon U; Pearce CL; Brüning T; Pike MC; Ko YD; Lissowska J; Figueroa J; Kupryjanczyk J; Chanock SJ; Dansonka-Mieszkowska A; Jukkola-Vuorinen A; Rzepecka IK; Pylkäs K; Bidzinski M; Kauppila S; Hollestelle A; Seynaeve C; Tollenaar RA; Durda K; Jaworska K; Hartikainen JM; Kosma VM; Kataja V; Antonenkova NN; Long J; Shrubsole M; Deming-Halverson S; Lophatananon A; Siriwanarangsan P; Stewart-Brown S; Ditsch N; Lichtner P; Schmutzler RK; Ito H; Iwata H; Tajima K; Tseng CC; Stram DO; van den Berg D; Yip CH; Ikram MK; Teh YC; Cai H; Lu W; Signorello LB; Cai Q; Noh DY; Yoo KY; Miao H; Iau PT; Teo YY; McKay J; Shapiro C; Ademuyiwa F; Fountzilas G; Hsiung CN; Yu JC; Hou MF; Healey CS; Luccarini C; Peock S; Stoppa-Lyonnet D; Peterlongo P; Rebbeck TR; Piedmonte M; Singer CF; Friedman E; Thomassen M; Offit K; Hansen TV; Neuhausen SL; Szabo CI; Blanco I; Garber J; Narod SA; Weitzel JN; Montagna M; Olah E; Godwin AK; Yannoukakos D; Goldgar DE; Caldes T; Imyanitov EN; Tihomirova L; Arun BK; Campbell I; Mensenkamp AR; van Asperen CJ; van Roozendaal KE; Meijers-Heijboer H; Collée JM; Oosterwijk JC; Hooning MJ; Rookus MA; van der Luijt RB; Os TA; Evans DG; Frost D; Fineberg E; Barwell J; Walker L; Kennedy MJ; Platte R; Davidson R; Ellis SD; Cole T; Bressac-de Paillerets B; Buecher B; Damiola F; Faivre L; Frenay M; Sinilnikova OM; Caron O; Giraud S; Mazoyer S; Bonadona V; Caux-Moncoutier V; Toloczko-Grabarek A; Gronwald J; Byrski T; Spurdle AB; Bonanni B; Zaffaroni D; Giannini G; Bernard L; Dolcetti R; Manoukian S; Arnold N; Engel C; Deissler H; Rhiem K; Niederacher D; Plendl H; Sutter C; Wappenschmidt B; Borg A; Melin B; Rantala J; Soller M; Nathanson KL; Domchek SM; Rodriguez GC; Salani R; Kaulich DG; Tea MK; Paluch SS; Laitman Y; Skytte AB; Kruse TA; Jensen UB; Robson M; Gerdes AM; Ejlertsen B; Foretova L; Savage SA; Lester J; Soucy P; Kuchenbaecker KB; Olswold C; Cunningham JM; Slager S; Pankratz VS; Dicks E; Lakhani SR; Couch FJ; Hall P; Monteiro AN; Gayther SA; Pharoah PD; Reddel RR; Goode EL; Greene MH; Easton DF; Berchuck A; Antoniou AC; Chenevix-Trench G; Dunning AM
Nat Genet; 2013 Apr; 45(4):371-84, 384e1-2. PubMed ID: 23535731
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
Goodwin PJ; Stambolic V; Lemieux J; Chen BE; Parulekar WR; Gelmon KA; Hershman DL; Hobday TJ; Ligibel JA; Mayer IA; Pritchard KI; Whelan TJ; Rastogi P; Shepherd LE
Breast Cancer Res Treat; 2011 Feb; 126(1):215-20. PubMed ID: 20976543
[TBL] [Abstract][Full Text] [Related]
15. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
André F; O'Regan R; Ozguroglu M; Toi M; Xu B; Jerusalem G; Masuda N; Wilks S; Arena F; Isaacs C; Yap YS; Papai Z; Lang I; Armstrong A; Lerzo G; White M; Shen K; Litton J; Chen D; Zhang Y; Ali S; Taran T; Gianni L
Lancet Oncol; 2014 May; 15(6):580-91. PubMed ID: 24742739
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Curigliano G; Pivot X; Cortés J; Elias A; Cesari R; Khosravan R; Collier M; Huang X; Cataruozolo PE; Kern KA; Goldhirsch A
Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
[TBL] [Abstract][Full Text] [Related]
17. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.
Johnston SR; Gómez H; Stemmer SM; Richie M; Durante M; Pandite L; Goodman V; Slamon D
Breast Cancer Res Treat; 2013 Feb; 137(3):755-66. PubMed ID: 23283526
[TBL] [Abstract][Full Text] [Related]
18. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
Pivot X; Schneeweiss A; Verma S; Thomssen C; Passos-Coelho JL; Benedetti G; Ciruelos E; von Moos R; Chang HT; Duenne AA; Miles DW
Eur J Cancer; 2011 Nov; 47(16):2387-95. PubMed ID: 21757334
[TBL] [Abstract][Full Text] [Related]
20. Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Bachelot T; Bajard A; Ray-Coquard I; Provencal J; Coeffic D; Agostini C; Boisseau M; Kaphan R; Dramais D; Oprea C; Ferri-Dessens RM; Guastalla JP; Perol D
Oncology; 2011; 80(3-4):262-8. PubMed ID: 21734418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
